TPST Tempest Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TPST

Price (delayed)

$3.69

Market cap

$81.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

$63.32M

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct ...

Highlights
The equity has grown by 48% YoY
The EPS has grown by 38% YoY and by 13% from the previous quarter
The quick ratio has soared by 178% since the previous quarter but it is down by 2.8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.millendo.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TPST
Market
Shares outstanding
22.19M
Market cap
$81.89M
Enterprise value
$63.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$28.04M
EBITDA
-$25.96M
Free cash flow
-$27.53M
Per share
EPS
-$1.91
Free cash flow per share
-$1.79
Book value per share
$1.39
Revenue per share
$0
TBVPS
$3.35
Balance sheet
Total assets
$51.6M
Total liabilities
$24.84M
Debt
$20.66M
Equity
$26.77M
Working capital
$30.95M
Liquidity
Debt to equity
0.77
Current ratio
4.29
Quick ratio
4.17
Net debt/EBITDA
0.72
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-82.1%
Return on equity
-283.9%
Return on invested capital
-107.2%
Return on capital employed
-66.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TPST stock price

How has the Tempest Therapeutics stock price performed over time
Intraday
4.24%
1 week
4.24%
1 month
-28%
1 year
84.5%
YTD
-16.14%
QTD
-5.63%

Financial performance

How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.16M
Net income
-$29.49M
Gross margin
N/A
Net margin
N/A
The net income has grown by 17% YoY and by 5% from the previous quarter
The company's operating income rose by 16% YoY and by 4.6% QoQ

Growth

What is Tempest Therapeutics's growth rate over time

Valuation

What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
2.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 38% YoY and by 13% from the previous quarter
The price to book (P/B) is 77% higher than the 5-year quarterly average of 1.5
The equity has grown by 48% YoY

Efficiency

How efficient is Tempest Therapeutics business performance
The ROE has plunged by 117% YoY but it has grown by 25% from the previous quarter
The company's return on assets fell by 42% YoY but it rose by 9% QoQ
TPST's return on invested capital is up by 40% year-on-year

Dividends

What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPST.

Financial health

How did Tempest Therapeutics financials performed over time
The company's total assets is 108% higher than its total liabilities
The quick ratio has soared by 178% since the previous quarter but it is down by 2.8% year-on-year
The current ratio has soared by 158% since the previous quarter but it has declined by 5% year-on-year
Tempest Therapeutics's debt is 23% less than its equity
The debt to equity has surged by 104% since the previous quarter but it has declined by 37% year-on-year
The equity has grown by 48% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.